Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.
Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study.
复制标题
Tin-117m(4)-DTPA 用于缓解骨转移疼痛：一项试点研究。
DOI：
--
复制
发表时间：
1995
影响因子：
9.3
通讯作者：
Thomas Dalessandro
中科院分区：
文献类型：
--
作者：
Harold L. Atkins;L. Mausner;Suresh C. Srivastava;G. Meinken;Cora J. Cabahug;Thomas Dalessandro
未标记
~（117）mSn（4+）-DTPA的物理和生物学特性表明，它是一种有效的姑息治疗骨转移性疼痛的药物。本研究的目的是评估这种药物是否可以有效地减轻疼痛，同时保护造血骨髓免受不良影响。
方法
本研究纳入了15名患有各种原发性癌症疼痛性骨转移的患者（10名男性和5名女性）。7例患者静脉注射117mSn 1.22 - 3.11 MBq/kg（第1组），8例患者静脉注射4.85 - 5.77 MBq/kg（第2组）。除1例外，所有患者均作为门诊患者接受治疗，并随访至少2个月。
结果
在第一组中，由于死亡或通过另一种方式对软组织疾病进行额外治疗，4名患者的疼痛缓解无法评估。1例患者疼痛未缓解，1例患者疼痛完全缓解，1例患者疼痛短暂缓解。未观察到骨髓毒性。对于第2组，3例患者疼痛完全缓解，2例缓解良好，2例部分缓解，1例在治疗后2个月发生病理性骨折时疼痛开始缓解。这些患者均未发生骨髓毒性。
结论
锡-117m（4+）-DTPA可减轻骨转移疼痛，而不会引起与骨髓相关的不良反应。需要进一步的研究来评估骨髓的耐受水平，并评估反应率和效果持续时间。
UNLABELLED
The physical and biological attributes of 117mSn(4+)-DTPA indicate that it should be an effective agent for palliative therapy of painful bony metastatic disease. The aim of this study was to evaluate whether or not this agent could effectively reduce pain while sparing the hemopoietic marrow from adverse effects.
METHODS
Fifteen patients (10 males and 5 females) with painful bony metastases from various primary cancers were included in the study. Seven patients received 1.22 to 3.11 MBq/kg of 117mSn intravenously (Group 1) and eight patients received 4.85 to 5.77 MBq/kg (Group 2). All but one were treated as outpatients and followed for a minimum of 2 mo.
RESULTS
In the first group, pain relief was non-assessable in four patients because of death or additional treatment of soft-tissue disease by another modality. One patient had no relief of pain, one had complete relief of pain and one had transient relief of pain. No myelotoxicity was observed. For Group 2, three patients achieved complete relief of pain, two good relief, two partial relief and one began to experience pain relief when he suffered a pathological fracture 2 mo post-treatment. None of these patients had myelotoxicity.
CONCLUSION
Tin-117m(4+)-DTPA can reduce pain from metastatic disease to bone without inducing adverse reactions related to bone marrow. Further studies are needed to assess tolerance levels for the bone marrow and to evaluate response rates and duration of effect.
放射免疫治疗中的时间剂量分割：对选择放射性核素的影响。
DOI：
--
发表时间：
1993
期刊：
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
影响因子：
--
作者：
Rao,DV;Howell,RW
通讯作者：
Howell,RW